Understanding Tysabri PML: What Symptoms Should You Monitor?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Literacy to Specific Legal Considerations

If you or a loved one is taking Tysabri, recognizing the early symptoms of progressive multifocal leukoencephalopathy (PML) can be critical. Decades of clinical experience with biologic therapies have established a clear need for vigilant monitoring. This page outlines the typical timeline of PML symptoms and what to watch for.

Understanding Tysabri and Its Association with PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its prescribing information carries a boxed warning stating that the drug increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML occurs when the JC virus infects and destroys oligodendrocytes, the cells that produce myelin in the central nervous system. Clinical presentation typically includes subacute onset of neurologic deficits such as cognitive impairment, motor weakness, gait disturbance, visual field defects, and speech difficulties. Diagnosis relies on brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid via polymerase chain reaction. The mechanistic pathway linking Tysabri to PML involves its pharmacologic action. Tysabri is a monoclonal antibody that binds to alpha-4 integrins on the surface of immune cells, preventing their adhesion to endothelial cells and subsequent migration into the brain. This reduces inflammation in multiple sclerosis but also impairs normal immune surveillance of the central nervous system. Under these conditions, latent JC virus can reactivate and cause lytic infection of oligodendrocytes. The FDA-approved labeling identifies three established risk factors for PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The labeling instructs healthcare professionals to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Adverse Event Reports and Clinical Monitoring

Adverse event reports submitted to the FDA Adverse Event Reporting System (FAERS) for Tysabri include a range of neurologic and systemic complaints. The most frequently reported events include fatigue (19,150 reports), multiple sclerosis relapse (16,691 reports), headache (9,626 reports), gait disturbance (9,422 reports), fall (7,939 reports), memory impairment (7,895 reports), asthenia (7,852 reports), malaise (7,319 reports), balance disorder (5,621 reports), hypoesthesia (5,343 reports), muscular weakness (4,535 reports), cognitive disorder (3,478 reports), and mobility decreased (3,769 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not establish causation, they reflect the spectrum of adverse experiences that may accompany Tysabri therapy and that could overlap with early PML symptoms. For patients in Florida who have developed PML after Tysabri use, legal considerations include the statute of limitations for filing a product liability claim. Florida law generally requires that a personal injury action be commenced within two years from the date the injury is discovered or should have been discovered through reasonable diligence. For PML, the timeline between Tysabri exposure and documented harm can be variable. PML typically occurs after months to years of treatment, with risk increasing beyond two years of therapy. The date of diagnosis—confirmed by MRI and JCV DNA testing—often serves as the point of discovery. Patients and their families should be aware that delays in diagnosis, which are common due to the nonspecific early symptoms, may affect the calculation of the limitations period. The adequacy of warnings provided by the manufacturer is a central issue in such claims. The boxed warning clearly states that Tysabri increases PML risk and identifies known risk factors, but plaintiffs may argue that the warnings were insufficient to alert prescribers and patients to the magnitude of risk or to the need for vigilant monitoring. The TOUCH program is designed to mitigate risk through controlled distribution and patient education, but its effectiveness in preventing PML is limited by the inherent latency of the disease. In summary, Tysabri-associated PML is a severe, often fatal complication linked to the drug's mechanism of action. The FDA-approved labeling provides explicit warnings and risk factor information. For affected individuals in Florida, the statute of limitations for legal action is typically two years from discovery of the injury, and the timeline from exposure to harm can span years. Legal counsel should be sought promptly to evaluate the specific circumstances of each case.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Florida?

Florida law generally requires that a personal injury action be commenced within two years from the date the injury is discovered or should have been discovered through reasonable diligence. For PML, the date of diagnosis often serves as the point of discovery.

What are the risk factors for developing PML while on Tysabri?

The FDA-approved labeling identifies three established risk factors: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.